Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Jeschke

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
The Journal of Investigative Dermatology|January 29, 2000
Mutation reports: epidermolysis bullosa simplex associated with severe mucous membrane involvement and novel mutations in the plectin geneM Kunz, F Rouan, L Pulkkinen, et al.
Infection|September 17, 2009
Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosisJ Riethmueller, S Junge, T W Schroeter, et al.
Scientific Reports|July 28, 2019
Global view of the RAF-MEK-ERK module and its immediate downstream effectorsCristina C Santini, James Longden, Erwin M Schoof, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 9, 2014
Phosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3Jacob A Galan, Kathryn M Geraghty, Geneviève Lavoie, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2014
Crenolanib is a selective type I pan-FLT3 inhibitorCatherine Choy Smith, Elisabeth A Lasater, Kimberly C Lin, et al.
Biochemistry|June 25, 2011
Defining the substrate specificity determinants recognized by the active site of C-terminal Src kinase-homologous kinase (CHK) and identification of β-synuclein as a potential CHK physiological substrateKim K Ia, Grace R Jeschke, Yang Deng, et al.
Blood|May 12, 2017
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysisCatherine C Smith, Amy Paguirigan, Grace R Jeschke, et al.
Investigational New Drugs|April 3, 2018
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibitionMargaret T Kasner, Rosemarie Mick, Grace R Jeschke, et al.
Genes & Development|June 15, 2017
CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignanciesKaosheng Lv, Jing Jiang, Ryan Donaghy, et al.
NPJ Breast Cancer|November 12, 2022
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancerIgor Makhlin, Nicholas P McAndrew, E Paul Wileyto, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
The Journal of Investigative Dermatology|January 29, 2000
Mutation reports: epidermolysis bullosa simplex associated with severe mucous membrane involvement and novel mutations in the plectin geneM Kunz, F Rouan, L Pulkkinen, et al.
Infection|September 17, 2009
Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosisJ Riethmueller, S Junge, T W Schroeter, et al.
Scientific Reports|July 28, 2019
Global view of the RAF-MEK-ERK module and its immediate downstream effectorsCristina C Santini, James Longden, Erwin M Schoof, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 9, 2014
Phosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3Jacob A Galan, Kathryn M Geraghty, Geneviève Lavoie, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2014
Crenolanib is a selective type I pan-FLT3 inhibitorCatherine Choy Smith, Elisabeth A Lasater, Kimberly C Lin, et al.
Biochemistry|June 25, 2011
Defining the substrate specificity determinants recognized by the active site of C-terminal Src kinase-homologous kinase (CHK) and identification of β-synuclein as a potential CHK physiological substrateKim K Ia, Grace R Jeschke, Yang Deng, et al.
Blood|May 12, 2017
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysisCatherine C Smith, Amy Paguirigan, Grace R Jeschke, et al.
Investigational New Drugs|April 3, 2018
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibitionMargaret T Kasner, Rosemarie Mick, Grace R Jeschke, et al.
Genes & Development|June 15, 2017
CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignanciesKaosheng Lv, Jing Jiang, Ryan Donaghy, et al.
NPJ Breast Cancer|November 12, 2022
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancerIgor Makhlin, Nicholas P McAndrew, E Paul Wileyto, et al.
Pageof 6